TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00724269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE RepleniSH
Description: Multi-Purpose Solution for soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus MPS
Description: Multi-Purpose Solution for soft contact lenses
Study: NCT03195660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASV Therapy
Description: AirCurve 10 ASV device set up in AutoSet mode
Study: NCT03709160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide 1 MG
Description: all patients will be taking the treatment recommended by heart failure guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide 1 MG
Description: all patients will be taking the treatment recommended by heart failure guidelines
Study: NCT06083116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide、Henagliflozin Proline
Description: Hydrochlorothiazide and Henagliflozin Proline
Study: NCT00345345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)
Description: Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
Study: NCT01581931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/metformin
Description: FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: single tablet Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: single tablet Linagliptin
Study: NCT02252094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prismalung
Description: Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-protective ventilation
Description: Ventilation with \</= 3ml/kg predicted body weight

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Lung Protective Ventilation
Description: Ventilation with 6ml/kg predicted body weight
Study: NCT02336711

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose escalation
Description: molecular imaging based radiotherapy dose escalation
Study: NCT04000750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Diet will be tracked and reported every day to a qualified dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Feeding
Description: Diet will be tracked and reported every day to a qualified dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: 8 weeks of supervised and programmed whole body resistance training, performed 4x per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 8 weeks of supervised and programmed whole body resistance training, performed 4x per week

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Consumed on all exercise days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Consumed on all exercise days.
Study: NCT02075723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Overfeeding (130 % of energy requirements )
Description: Overfeeding (130 % of energy requirements )

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Overfeeding (130 % of energy requirements )
Description: Overfeeding (130 % of energy requirements )

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours per night)
Description: Sleep restriction (4 hours per night)
Study: NCT02722434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03605459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort Plug™
Study: NCT01432340

Intervention type: BIOLOGICAL
Intervention: Seasonal influenza vaccine
Description: annual recommended Southern Hemisphere vaccine
Study: NCT02722434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler Therapy
Description: Undergo Scrambler therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02722434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Undergo TENS
Study: NCT02720432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT
Description: Constraint-induced movement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT
Description: hand-arm bimanual intensive training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: baby-massage
Description: instructions for baby-massage
Study: NCT04163432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
Study: NCT03774849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 532nm fractional handpiece
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 730nm wavelength
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 1064nm fractional handpiece
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser
Study: NCT05249153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose of dexmedetomidine with sufentanil
Description: low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose of dexmedetomidine with sufentanil
Description: high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
Study: NCT03981887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin
Description: Nafithromycin 200 mg as IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo administered as IV infusion
Study: NCT02704702

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin
Study: NCT02885740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantification assay of adenosine and methionine cycle metabolites

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantification assay of adenosine and methionine cycle metabolites

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphism analysis of genes related to adenosine metabolism and methionine cycle

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Polymorphism analysis of genes related to adenosine metabolism and methionine cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative and qualitative nutritional evaluation
Description: Questionnaire on consumption of 208 foods and drinks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative and qualitative nutritional evaluation
Description: Questionnaire on consumption of 208 foods and drinks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study: NCT00167141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of hormonal male contraceptive
Description: testosterone injections 4 times
Study: NCT04120753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLOMAX 20/5/5mg
Description: Tablets, Oral, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLOMAX 20/5/10mg
Description: Tablets, Oral, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan 20 mg/Amlodipine 5 mg
Description: Tablets, Oral, QD
Study: NCT02743949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Vonoprazan over-encapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan over-encapsulated capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole over-encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole over-encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole over-encapsulated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole Placebo
Description: Esomeprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Placebo
Description: Esomeprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Placebo
Description: Esomeprazole placebo-matching capsules
Study: NCT03389555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C, vitamin B1, hydrocortisone
Description: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT03806556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV medication administered after patient meets inclusion/exclusion criteria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV medication administered after patient meets inclusion/exclusion criteria
Study: NCT03109093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab.
Study: NCT02483728

Intervention type: OTHER
Group type: OTHER
Intervention: Patch Test
Description: Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.

Intervention type: OTHER
Group type: OTHER
Intervention: Patch Test
Description: Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
Study: NCT00638378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 25 mg tablets taken with water twice a day.
Study: NCT00793403

Intervention type: OTHER
Intervention: As per routinary clinical care
Description: As per routine clinical care
Study: NCT02957877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
Study: NCT03024450

Intervention type: DRUG
Intervention: H+CT
Description: All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
Study: NCT01265732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 100mg, dispersion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 100mg, suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 300mg, suspension
Study: NCT04405986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potentials (AEP)
Description: Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blink and Masseter Inhibitory Reflex
Description: Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
Study: NCT01616524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (pegIFNλ)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (pegIFNλ)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
Study: NCT03201926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mealworms
Description: 10g , 3 times a day , po, 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: grain powder
Description: grain powder, 10g ,3times one day,2months
Study: NCT02253563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Study: NCT02352454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study: NCT05210517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: 25 once daily one week treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromaron
Description: 100 mg once daily 1 one week treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG + benzbromarone 100 mg
Description: combined treatment once daily for one week
Study: NCT00592163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101-C (Darinaparsin)
Description: Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
Study: NCT05027126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen 25 MG
Description: Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose Dexketoprofen-Vitamin B Complex
Description: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
Study: NCT01320319

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form, 960 mg to be taken three times a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Nutritional Supplementation with EPA
Description: Capsule form, EPA, 960mg to be taken three times a day.
Study: NCT04545190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: To investigate the effects of glucose intake during resistance training on muscle biological adaptations

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: To investigate the effects of glucose intake during resistance training on muscle biological adaptations
Study: NCT03558334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
Study: NCT03010137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Negative Pressure Wound Therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Closure with Skin Glue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO (Smith&Nephew)
Description: Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: Final wound closure with skin glue.
Study: NCT00322023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Study: NCT03336801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Back Surgery
Description: All patients undergo basic back surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Back Surgery
Description: All patients undergo basic back surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia on propofol alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia on sevoflurane alone.
Study: NCT00369174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Given orally